Abstract |
Hematopoietic stem cells (HSCs) are the source of all blood lineages, and HSCs must balance quiescence, self-renewal, and differentiation to meet lifelong needs for blood cell development. Transformation of HSCs by the breakpoint cluster region-ABL tyrosine kinase (BCR-ABL) oncogene causes chronic myelogenous leukemia (CML). The E-twenty six ( ets) transcription factor GA binding protein (GABP) is a tetrameric transcription factor complex that contains GABPα and GABPβ proteins. Deletion in bone marrow of Gabpa, the gene that encodes the DNA-binding component, caused cell cycle arrest in HSCs and profound loss of hematopoietic progenitor cells. Loss of Gabpα prevented development of CML, although mice continued to generate BCR-ABL-expressing Gabpα-null cells for months that were serially transplantable and contributed to all lineages in secondary recipients. A bioinformatic screen identified the serine-threonine kinase protein kinase D2 (PRKD2) as a potential effector of GABP in HSCs. Prkd2 expression was markedly reduced in Gabpα-null HSCs and progenitor cells. Reduced expression of PRKD2 or pharmacologic inhibition decreased cell cycling, and PRKD2 rescued growth of Gabpα-null BCR-ABL-expressing cells. Thus, GABP is required for HSC cell cycle entry and CML development through its control of PRKD2. This offers a potential therapeutic target in leukemia.
|
Authors | Zhong-Fa Yang, Haojian Zhang, Leyuan Ma, Cong Peng, Yaoyu Chen, Junling Wang, Michael R Green, Shaoguang Li, Alan G Rosmarin |
Journal | Proceedings of the National Academy of Sciences of the United States of America
(Proc Natl Acad Sci U S A)
Vol. 110
Issue 6
Pg. 2312-7
(Feb 05 2013)
ISSN: 1091-6490 [Electronic] United States |
PMID | 23345428
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Benzamides
- GA-Binding Protein Transcription Factor
- Gabpa protein, mouse
- Piperazines
- Protein Kinase D2
- Protein Kinase Inhibitors
- Pyrimidines
- Imatinib Mesylate
- Protein Kinases
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology)
- Benzamides
- Cell Cycle
- GA-Binding Protein Transcription Factor
(deficiency, genetics, metabolism)
- Gene Expression
- Hematopoietic Stem Cells
(drug effects, metabolism, pathology)
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
(drug therapy, etiology, genetics, metabolism)
- Mice
- Mice, Transgenic
- Piperazines
(pharmacology)
- Protein Kinase D2
- Protein Kinase Inhibitors
(pharmacology)
- Protein Kinases
(genetics, metabolism)
- Pyrimidines
(pharmacology)
|